The Aroon Indicator for LXRX entered a downward trend on October 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator formed such a pattern. In 205 of the 222 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for LXRX turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LXRX's RSI Oscillator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where LXRX advanced for three days, in 198 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
LXRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.028) is normal, around the industry mean (3.009). P/E Ratio (-9.875) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.570) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. LXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZURA advanced for three days, in 152 of 187 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ZURA's RSI Oscillator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ZURA as a result. In 48 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for ZURA just turned positive on October 07, 2026. Looking at past instances where ZURA's MACD turned positive, the stock continued to rise in 35 of 60 cases over the following month. The odds of a continued upward trend are 58%.
The 10-day moving average for ZURA crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
The 50-day moving average for ZURA moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ZURA broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZURA entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.945) is normal, around the industry mean (3.009). P/E Ratio (-3.571) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ZURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LXRX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 89 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 65 | |
P/E GROWTH RATING 1..100 | 15 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| LXRX | ZURA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 78% |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 68% |
| Momentum ODDS (%) | N/A | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 74% |
| Advances ODDS (%) | 1 day ago 85% | 7 days ago 81% |
| Declines ODDS (%) | 7 days ago 86% | 2 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 87% | 1 day ago 47% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 78% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LXRX’s FA Score shows that 2 FA rating(s) are green while ZURA’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LXRX’s TA Score shows that 4 TA indicator(s) are bullish while ZURA’s TA Score has 4 bullish TA indicator(s).
LXRX (@Biotechnology) experienced а -1.86% price change this week, while ZURA (@Biotechnology) price change was -5.44% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
LXRX is expected to report earnings on Nov 05, 2026.
ZURA is expected to report earnings on Nov 18, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ZURA has been loosely correlated with VIR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ZURA jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To ZURA | 1D Price Change % | ||
|---|---|---|---|---|
| ZURA | 100% | +4.99% | ||
| VIR - ZURA | 44% Loosely correlated | +5.19% | ||
| RCUS - ZURA | 42% Loosely correlated | +7.27% | ||
| TNXP - ZURA | 41% Loosely correlated | +0.87% | ||
| FDMT - ZURA | 39% Loosely correlated | +6.59% | ||
| LXRX - ZURA | 39% Loosely correlated | +1.94% | ||
More | ||||